University Of Washington AIDS Clinical Trial Unit: AIDS Ribbon University Of Washington AIDS Clinical Trial Unit Header
UW AIDS Clinical Trial Unit Home Page UW AIDS Clinical Trial Unit Studies UW AIDS Clinical Trial Unit Staff UW AIDS Clinical Trial Unit Links
UW AIDS Clinical Trial Unit Positivemente Latino UW AIDS Clinical Trial Unit Outreach Page UW AIDS Clinical Trial Unit Contact Us Page
University of Washington Seal
5305 FACT SHEET ( Next-PrEP Study )
A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir disoproxil fumarate (MVC+TDF), or Tenofovir disoproxil fumarate + Emtricitabine (TDF+FTC) For Pre-Exposure Prophylaxis (PrEP) To Prevent HIV Transmission in At-Risk Men Who Have Sex with Men and in At Risk Women (ACTG 5305)
Purpose of This Trial:
To assess the safety and tolerability of four antiretroviral (ARV) drug regimens used as pre-exposure prophylaxis (PrEP) to prevent HIV transmission in HIV- negative men or women who have sex with men who are HIV positive or unknown of HIV status

You may be eligible if you are:
  • Born male or female, age 18y/o or greater
  • History of receptive or insertive anal intercourse or vaginal intercourse without use of condoms with at least one HIV-infected male partner or male partner of unknown HIV serostatus within three (3) months of study entry (provided by self-report)
  • Co-enrollment in any other HIV interventional research study (provided by self-report or other available documentation) or prior enrollment and receipt of active arm (i.e., NOT a placebo) of a HIV vaccine trial (provided by available documentation) is prohibited.
  • For women- not pregnant, planning pregnancy or currently breast feeding Use of ARV therapy (e.g., for PEP or PrEP) in the 90 days prior to study entry
  • Willing to undergo all required study procedures (including sexual assessment by computer assisted self-interview, use of the drug monitoring device, and SMS [i.e., texting])
Medications While On Study:
Maraviroc, Emtricitabine, Tenofovir, and placebo provided
Length of Study:
About 49 weeks
Schedule of Study Appointments:
Screening, Entry, and weeks 2, 4, 8, 16, 24, 32, 40, 48 and 49.
Reimbursement:
Clinical exams, study medications, and lab tests are provided at no cost. You will receive $20 per visit starting at Entry.
Contact:
The ACTU Screening Nurse at 206-744-3184.
return to top of page

Home Research Staff Links Latino Outreach Contact Site Map

© University of Washington AIDS Clinical Trial Unit, updated 05/20/2013.